Gastric Cancer: Preoperative TNM Staging With Individually Adjusted Computed Tomography Scanning Phase.
Cen Shi,Bo Liu,Jing Yan,Huanhuan Liu,Zilai Pan,Weiwu Yao,Fuhua Yan,Huan Zhang
DOI: https://doi.org/10.1097/RCT.0000000000000339
2016-01-01
Journal of Computer Assisted Tomography
Abstract:OBJECTIVE:The aim of this study was to evaluate test bolus scan technology on preoperative diagnostic performance, vascular enhancement, and artery visualization for gastric cancer.
METHODS:The institutional review board approved this study. Fifty-four patients in protocol 1 were resigned to a fixed delay time scan method, and their images were obtained in the late arterial phase (AP) and portal venous phase (PP), with start delays of 40 and 70 seconds, respectively. Fifty-six patients in protocol 2 had undergone the test bolus method first and received the time to peak enhancement of the aorta. Their images were obtained in the AP and PP with start delays in the time to peak enhancement and 20 seconds after the AP, respectively. Two radiologists performed consensus interpretation of the preoperative TNM staging, vascular enhancement, tumor contrast-to-noise ratio (CNR) and artery visualization between the 2 protocols.
RESULTS:There is no significant difference in the T, N, and M staging diagnostic accuracy between the protocols (P = 0.41, P > 0.99, and P = 0.34, respectively). For serosa-negative (T1, T2, and T3) tumors, the diagnostic accuracy obtained with protocol 2 was superior to that obtained with protocol 1 (P = 0.04). Protocol 2 was superior for perigastric vessel enhancement (left gastric artery, right gastroepiploic artery, and splenic artery; P < 0.001, P < 0.001, and P = 0.001, respectively). The stomach-to-tumor CNR during the PP of protocol 2 was significantly higher than that during either the AP or PP of protocol 1 (P = 0.004 and P = 0.001, respectively). The mean rankings of the artery visualization were significantly higher with protocol 2 than with protocol 1 (P < 0.001).
CONCLUSIONS:The dual-phase scan with test bolus technology could improve the tumor CNR and had high staging accuracy for serosa-negative tumors as well as high perigastric artery enhancement, yielding satisfactory artery visualization for diagnosis.